Dr. Strickler on the Efficacy of Tucatinib/Trastuzumab in HER2+ Colorectal Cancer

Video

John H. Strickler, MD, discusses the efficacy of tucatinib plus trastuzumab in HER2-positive colorectal cancer.

John H. Strickler, MD, medical oncologist, Duke Cancer Center, Duke Health, discusses the efficacy of tucatinib (Tukysa) plus trastuzumab (Herceptin) in HER2-positive colorectal cancer (CRC).

The phase 2 MOUNTAINEER trial (NCT03043313) examined the safety and efficacy of tucatinib in combination with trastuzumab or tucatinib alone in patients with HER2-positive CRC.

The randomized, open label study met its primary endpoint of overall response rate (ORR) per blinded independent central review, Strickler says. The 84 patients who received the tucatinib/trastuzumab combination achieved an ORR 38.1%, and the investigator-assessed ORR was 43%, Strickler explains. Notably, the responses were durable, with median duration of response greater of 12.4 months, Strickler adds. The progression-free survival was 8.2 months, and the median overall survival was 24.1 months, Stickler continues.

The hope is to see this meaningful clinical activity translate to practice, Strickler continues. The regimen was well tolerated, with most of the adverse effects experienced were mild to moderate in severity, Strickler says. No treatment-related deaths were reported, and most patients found the regimen manageable with routine supportive care, Strickler concludes.

Related Videos
Robert Huddart, PhD, leader, Clinical Academic Radiotherapy Team, The Institute of Cancer Research; professor, urological cancer, honorary consultant, Urological Oncology, The Royal Marsden NHS Foundation Trust
Ariel Grajales-Cruz, MD
Nikhil A. Gopal, MD
Jaime R. Merchán, MD, Sylvester Comprehensive Cancer Center
Rona Yaeger, MD
Jeremy L. Ramdial, MD, assistant professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Alexandra Gomez Arteaga, MD, Weill Cornell Medicine/New York-Presbyterian Hospital
Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
Alice Bertaina, MD, PhD
Jeffery Auletta, MD, The Ohio State University College of Medicine